Risks and management of side effects of targeted therapies

被引：0

作者：

Gutzmer, R. ^{[1
]}

Strumberg, D. ^{[2
]}

机构：

[1] Hannover Med Sch, Hauttumorzentrum Hannover HTZH, Klin Dermatol Allergol & Venerol, Hannover, Germany

[2] Klin Ruhr Univ Bochum, Marienhosp Herne, Med Klin 3, Herne, Germany

来源：

ONKOLOGE | 2013年 / 19卷 / 10期

关键词：

Targeted therapies; Immunotherapy; Side effects; Molecular signalling pathways; Multikinase inhibitors; TYROSINE KINASE INHIBITORS; INDUCED DIARRHEA; CARDIOTOXICITY; MECHANISMS; HYPERTENSION;

D O I：

10.1007/s00761-013-2500-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeted therapies are increasingly being used in the medicinal therapy of tumors. The targeted manipulation of molecular signalling pathways or immune reactions can result in adverse effects which are in part novel and require special attention. Research and analysis of the literature. This article reviews the side effects of multikinase inhibitors, MAP kinase inhibitors (in particular EGFR, KIT and BRAF inhibitors) and CTLA-4 inhibitors and discusses the management. The knowledge of these side effects must be thoroughly inccorporated in the clinical examination and the treating physician should have a comprehensive knowledge of them.

引用

页码：863 / 869

页数：7

共 50 条

[41] Risks and side effects in the medical management of benign prostatic hyperplasia
Halawani, Abdulghafour
Paterson, Ryan
Zhong, Tianshuang
Du, Katie
Ren, Runhan
Forbes, Connor M.
PROSTATE INTERNATIONAL, 2024, 12 (02) : 57 - 64
[42] On Risks and Side Effects
Ospelt, Nina
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2016, 233 (03) : 238 - 239
[43] Risks and Side Effects
Ospelt, Nina
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (01) : 64 - 65
[44] Side effects' assessments of new targeted therapies by a clinical pharmacist in oncology outpatient clinic
Ekincioglu, Aygin Bayraktar
Kucuk, Esra
Kelleci, Burcu
Demirkan, Kutay
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 227 - 228
[45] Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies)
de Castro, Gilberto, Jr.
Awada, Ahmad
CURRENT OPINION IN ONCOLOGY, 2006, 18 (04) : 307 - 315
[46] Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma Guide for the Hepatologist
Winters, Adam C.
Bedier, Fatima
Saab, Sammy
CLINICS IN LIVER DISEASE, 2020, 24 (04) : 755 - 769
[47] Benefit/risk of therapies for rheumatoid arthritis: Underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies
Pincus, T
Kavanaugh, A
Sokka, T
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (05) : S2 - S11
[48] Side effects of oncologic therapies
Zimmer, Lisa
Hassel, Jessica C.
DERMATOLOGIE, 2024, 75 (06): : 437 - 439
[49] Management of targeted therapies in hemodialysis patients
Janus, Nicolas
Launay-Vacher, Vincent
Deray, Gilbert
Islam, Mohamed Shariful
Thyss, Antoine
Thariat, Juliette
BULLETIN DU CANCER, 2012, 99 (03) : 381 - 388
[50] Management of ECD: the era of targeted therapies
Abla, Oussama
BLOOD, 2020, 135 (22) : 1919 - 1920

← 1 2 3 4 5 →